Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo.

[1]  Mark Voorneveld,et al.  Preparation , 2018, Games Econ. Behav..

[2]  V. Torchilin,et al.  Surface modification of liposomes with rhodamine-123-conjugated polymer results in enhanced mitochondrial targeting , 2011, Journal of drug targeting.

[3]  K. Lim,et al.  Intracellular organelle-targeted non-viral gene delivery systems. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[4]  J. Benoit,et al.  Mitochondrial targeting by use of lipid nanocapsules loaded with SV30, an analogue of the small-molecule Bcl-2 inhibitor HA14-1. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[5]  V. Torchilin,et al.  Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol , 2010, Journal of liposome research.

[6]  Yuquan Wei,et al.  Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[7]  L. Galluzzi,et al.  Targeting mitochondria for cancer therapy , 2010, Nature Reviews Drug Discovery.

[8]  B. Zhivotovsky,et al.  Mitochondrial regulation of cell death: processing of apoptosis-inducing factor (AIF). , 2010, Biochemical and biophysical research communications.

[9]  Ji‐Xin Cheng,et al.  Cationic amphiphilic polyproline helix P11LRR targets intracellular mitochondria. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[10]  G. Campiani,et al.  Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. , 2009, Cancer research.

[11]  G. Trapani,et al.  Peripheral benzodiazepine receptor ligand-PLGA polymer conjugates potentially useful as delivery systems of apoptotic agents. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[12]  C. Pan,et al.  In vitro and in vivo evaluation of a non-carbohydrate targeting platform for lysosomal proteins. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[13]  T. Minko,et al.  Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[14]  J. Kopeček,et al.  Novel HPMA copolymer-bound constructs for combined tumor and mitochondrial targeting. , 2008, Molecular pharmaceutics.

[15]  V. Torchilin,et al.  Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. , 2008, Nano letters.

[16]  M. Murphy,et al.  Targeting lipophilic cations to mitochondria. , 2008, Biochimica et biophysica acta.

[17]  Nektarios Tavernarakis,et al.  No death without life: vital functions of apoptotic effectors , 2008, Cell Death and Differentiation.

[18]  Stefan Trapp,et al.  Mitochondriotropics: a review of their mode of action, and their applications for drug and DNA delivery to mammalian mitochondria. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[19]  Dae-Duk Kim,et al.  Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Yuma Yamada,et al.  Mitochondrial drug delivery and mitochondrial disease therapy--an approach to liposome-based delivery targeted to mitochondria. , 2007, Mitochondrion.

[21]  Marty C. Brandon,et al.  Mitochondrial mutations in cancer , 2006, Oncogene.

[22]  E. Gottlieb,et al.  Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer , 2006, Oncogene.

[23]  Vladimir P Torchilin,et al.  Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. , 2006, Annual review of biomedical engineering.

[24]  Robin A. J. Smith,et al.  Targeting an antioxidant to mitochondria decreases cardiac ischemia‐reperfusion injury , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  M. Ivannikov,et al.  [Ca2+]i Signaling between Mitochondria and Endoplasmic Reticulum in Neurons Is Regulated by Microtubules , 2005, Journal of Biological Chemistry.

[26]  V. Torchilin,et al.  Mitochondriotropic Liposomes , 2005, Journal of liposome research.

[27]  D. Hoekstra,et al.  Effective intracellular delivery of oligonucleotides in order to make sense of antisense. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[28]  John Calvin Reed,et al.  Conversion of Bcl-2 from Protector to Killer by Interaction with Nuclear Orphan Receptor Nur77/TR3 , 2004, Cell.

[29]  K. Bhalla.  Microtubule-targeted anticancer agents and apoptosis , 2003, Oncogene.

[30]  S. Dimauro,et al.  Medicinal and genetic approaches to the treatment of mitochondrial disease. , 2003, Current medicinal chemistry.

[31]  Robin A. J. Smith,et al.  Mitochondria‐targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  F. Dosio,et al.  Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Robin A. J. Smith,et al.  Delivery of bioactive molecules to mitochondria in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Murdock,et al.  Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  J. Kopeček,et al.  Cytoplasmic delivery and nuclear targeting of synthetic macromolecules. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[36]  Robin A. J. Smith,et al.  Selective Targeting of a Redox-active Ubiquinone to Mitochondria within Cells , 2001, The Journal of Biological Chemistry.

[37]  John Calvin Reed,et al.  Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. , 2000, Science.

[38]  D. Wallace.  Mitochondrial diseases in man and mouse. , 1999, Science.

[39]  G M Cohen,et al.  Caspases: the executioners of apoptosis. , 1997, The Biochemical journal.

[40]  Xiaodong Wang,et al.  Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.

[41]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[42]  A. Gabizon,et al.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Harding,et al.  Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies , 1988, Nature.

[44]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[45]  P. Wipf,et al.  Targeting mitochondria. , 2008, Accounts of chemical research.

[46]  Lorenzo Galluzzi,et al.  Mitochondrial membrane permeabilization in cell death. , 2007, Physiological reviews.

[47]  D. Wallace,et al.  Mitochondria and cancer: Warburg addressed. , 2005, Cold Spring Harbor symposia on quantitative biology.